Register entry
- Registered sites
- 0
- Active NDC listings
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
22 active NDC listings: 1 drug for further processing, 1 human prescription drug. By marketing category: BLA 1, DRUG FOR FURTHER PROCESSING 1.
| Dosage form | NDCs |
|---|---|
| injection, solution, concentrate | 1 |
| solution | 1 |
| Route | NDCs |
|---|---|
| intravenous | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| macrogenics, inc | 2 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| MARGENZA | margetuximab-cmkb | injection, solution, concentrate, intravenous | 74527-022BLA |
| - | retifanlimab | solution | 74527-012DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing margetuximab-cmkb
- TerSera Therapeutics LLC0 sites · 9 NDC
Enquiry
Common questions
- Is MacroGenics, Inc FDA approved?
- MacroGenics, Inc holds no registered establishment of its own; 2 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does MacroGenics, Inc make?
- 2 products are listed under MacroGenics, Inc in the openFDA NDC Directory, most often as injection, solution, concentrate; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.